<DOC>
	<DOC>NCT03096834</DOC>
	<brief_summary>The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have unsuccessfully failed other preventive migraine treatments.</brief_summary>
	<brief_title>A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Documented history of migraine in the 12 months prior to screen 414 days per month of migraine symptoms &gt;=80% diary compliance during the Baseline period Failure of previous migraine prophylactic treatments &gt;50 years old at migraine onset Pregnant or nursing History of cluster or hemiplegic headache Evidence of seizure or psychiatric disorder Score of 19 or higher on BDI Active chronic pain syndrome Cardiac or hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>attack</keyword>
	<keyword>headache</keyword>
	<keyword>episodic</keyword>
	<keyword>aura</keyword>
	<keyword>AMG 334</keyword>
	<keyword>CGRP receptor agonist</keyword>
	<keyword>erenumab</keyword>
</DOC>